<DOC>
	<DOCNO>NCT00660673</DOCNO>
	<brief_summary>The primary objective provide continue access subject would like continue levodopa-carbidopa intestinal gel ( LCIG ) , completion open-label study ( S187.3.003 S187.3.004 ) .</brief_summary>
	<brief_title>Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel Advanced PD</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>The subject complete participation Study S187.3.003 S187.3.004 ; , opinion Principal Investigator , would benefit longterm treatment LCIG . For Canada , subject allow participate S187.3.005 study minimum 6 month exposure LCIG S187.3.004 study . The subject must able understand nature study must provide write informed consent prior conduct study related procedure . If subject capacity provide inform consent , full informed consent must obtain subject 's legally authorize representative . Consenting perform accord local regulation . Medical , laboratory , psychiatric , surgical issue deem investigator clinically significant could interfere subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>levodopa/carbidopa intestinal gel</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Carbidopa</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Severe Motor Fluctuations</keyword>
	<keyword>Levodopa</keyword>
</DOC>